TWC
BCRX icon

TD Waterhouse Canada’s BioCryst Pharmaceuticals BCRX Stock Holding History

TD Waterhouse Canada’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$932 – 1719
2023
Q2 		$932 Hold
100
– – ﹤0.01% 1606
2023
Q1 		$1.13K Buy
+100
New +$963 ﹤0.01% 1587

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

TD Waterhouse Canada's BCRX Position: Q3 2023 in Review

TD Waterhouse Canada sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 100 shares — an estimated $932 sold.

TD Waterhouse Canada first reported a position in BCRX in Q1 2023 and held it in 2 quarters. The position peaked at $1.13K in Q1 2023. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • TD Waterhouse Canada reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • TD Waterhouse Canada sold 100 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $932.
  • TD Waterhouse Canada first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • TD Waterhouse Canada's BioCryst Pharmaceuticals position peaked at $1.13K in Q1 2023.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on TD Waterhouse Canada's 13F filing for Q3 2023, filed 13 Nov 2023.